New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease

scientific article published on June 2016

New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease is …
instance of (P31):
scholarly articleQ13442814
review articleQ7318358

External links are
P356DOI10.1111/BCP.13022
P932PMC publication ID5061796
P698PubMed publication ID27245261

P50authorStephan MielkeQ40593184
Mathias LutzQ53071968
P2093author name stringMathias Lutz
P2860cites workThe PI3K pathway as drug target in human cancerQ24632283
mTOR: from growth signal integration to cancer, diabetes and ageingQ24633662
PI3K/Akt/mTOR inhibitors in breast cancerQ26771394
Targeting the mTOR signaling pathway in neuroendocrine tumorsQ26852089
TOR signaling in growth and metabolismQ27860757
Defining the role of mTOR in cancerQ28235431
Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host diseaseQ33340454
Rapamycin (sirolimus) for treatment of chronic graft-versus-host diseaseQ33364353
Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysisQ33416874
Sirolimus and everolimus in kidney transplantationQ33423446
Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host DiseaseQ33424311
Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host DiseaseQ33649332
Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation.Q33653718
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.Q34077792
A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantationQ34272554
Medical treatment of neuroendocrine tumoursQ34503867
Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantationQ35184589
Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoidsQ35193740
Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.Q35231363
Graft-versus-host disease prophylaxis after transplantation: a network meta-analysisQ35499395
Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host diseaseQ35800856
Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysisQ35900978
The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.Q36216192
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantationQ36662042
The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trialQ36734547
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyQ36862931
Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantationQ36868082
mTOR and lymphocyte metabolismQ37137525
Comorbidity burden in patients with chronic GVHDQ37609043
Quality of life associated with sirolimus for prevention of graft-versus-host disease: results from a randomized trial.Q37618931
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the EvidenceQ37639714
The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.Q37670062
Defining the role of sirolimus in the management of graft-versus-host disease: from prophylaxis to treatmentQ38024589
mTOR, metabolism, and the regulation of T-cell differentiation and functionQ38034265
mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practiceQ38092421
Drug interactions and the pharmacist: focus on everolimusQ38113771
Current state of mTOR targeting in human breast cancerQ38232417
Future perspectives for mTOR inhibitors in renal cell cancer treatmentQ38372445
Everolimus and sirolimus in transplantation-related but different.Q38442560
Clinical Management of Posterior Reversible Encephalopathy Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series and Review of the LiteratureQ38544555
The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic modelQ38976077
Sjögren-Type Syndrome After Allogeneic Bone-Marrow TransplantationQ39174395
SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivoQ41099411
Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem CellsQ41206823
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioningQ41876102
Rapamycin inhibits human laryngotracheal stenosis-derived fibroblast proliferation, metabolism, and function in vitroQ41977478
Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermatesQ42212846
Sirolimus for treatment of steroid-refractory acute graft-versus-host diseaseQ43228479
Rapamycin for refractory acute graft-versus-host diseaseQ43246106
Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus.Q43413019
A dedicated GvHD clinic may improve the quality of life for allogeneic stem cell transplant survivorsQ43587849
Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trialQ43968027
Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantationQ44081953
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantationQ44107506
Antileukemic activity of rapamycin in acute myeloid leukemia.Q45154681
Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort studyQ46244557
Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host diseaseQ46617730
High prevalence of distress in patients after allogeneic hematopoietic SCT: fear of progression is associated with a younger age.Q47928634
GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT.Q48261069
Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.Q51064103
Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial.Q51067478
Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control.Q53166890
Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.Q53550301
Aberrant germinal center formation, follicular T-helper cells, and germinal center B-cells were involved in chronic graft-versus-host disease.Q54272726
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.Q54596807
In vivo inhibition of cytokine responsiveness and graft-versus-host disease mortality by rapamycin leads to a clinical-pathological syndrome discrete from that observed with cyclosporin AQ71029782
Inhibition by rapamycin of PDGF- and bFGF-induced human tenon fibroblast proliferation in vitroQ71508769
The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipientsQ81227390
Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitorsQ84704396
[Delayed wound healing during therapy of cutaneous graft-versus-host disease with everolimus]Q87373649
P433issue5
P407language of work or nameEnglishQ1860
P304page(s)1171-1179
P577publication date2016-06-01
P1433published inBritish Journal of Clinical PharmacologyQ176044
P1476titleNew perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease
P478volume82